NCT03520504已完成1 期
A Phase Ib Study With Dose Expansion Cohort of Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 16
- 主要终点
- number of patients with dose-limiting toxicity
研究概览
简要总结
The purpose of this study is to find the safest and most effective dose for delivering proton beam to the space containing CSF, brain, and spinal cord, in treating leptomeningeal metastases. The researchers think that using proton beam radiation to treat the space containing CSF, brain, and spinal cord, instead of treating only the areas where the metastasized tumor cells are causing symptoms, would improve the treatment of this disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 10 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female subjects must either be of non-reproductive potential (i.e. post-menopausal by history: >/= 60 years old and no menses for 1> year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test within 2 weeks prior to starting treatment.
- •Patient with solid tumor malignancy with leptomeningeal metastases established radiographically and/or through CSF cytology.
- •Age ≥ 10 years.
- •For adult patient, the patient is able to provide informed consent. For pediatric patient, a parent is able to provide informed consent.
- •Patient at reproductive potential must agree to practice an effective contraceptive method.
- •Adequate bone marrow function:
- •Hemoglobin ≥ 8g/dL
- •Absolute neutrophil count ≥500/mm^3
- •Platelet count ≥ 100,000/mm^3
排除标准
- •Patient with multiple, serious major neurologic deficits including encephalopathy.
- •Patient with extensive systemic disease and without reasonable systemic treatment options.
- •Patient who is unable to undergo MRI brain and spine with gadolinium contrast.
- •Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.
- •Pregnant or lactating women.
结局指标
主要结局
number of patients with dose-limiting toxicity
时间窗: 2 years
will be assessed by physician-graded CTCEAv4
次要结局
未报告次要终点
研究者
研究点 (16)
Loading locations...
相似试验
已完成
2 期
Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the ProstateProstate CancerNCT00585962Massachusetts General Hospital57
已完成
不适用
Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic MetastasesHepatocellular CancerHepatic MetastasesCholangiocarcinomaNCT00465023Massachusetts General Hospital16
招募中
不适用
Escalated Dose Proton Therapy Within the Multimodality Treatment of Glioblastoma PatientsGlioblastomaNCT05768087University of Aarhus36
进行中（未招募）
2 期
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate CancerAdenocarcinoma of the ProstateNCT03624660University of Florida100
终止
1 期
Study of Hypofractionated Proton Radiation Therapy in Thoracic MalignanciesThymic CancerNon-small Cell Lung CancerCarcinoidLung CancerSmall Cell Lung CancerNCT01165658M.D. Anderson Cancer Center30